CN100518721C - 一种含有乌头碱的肠溶速释片及其制备方法 - Google Patents
一种含有乌头碱的肠溶速释片及其制备方法 Download PDFInfo
- Publication number
- CN100518721C CN100518721C CNB2006100486072A CN200610048607A CN100518721C CN 100518721 C CN100518721 C CN 100518721C CN B2006100486072 A CNB2006100486072 A CN B2006100486072A CN 200610048607 A CN200610048607 A CN 200610048607A CN 100518721 C CN100518721 C CN 100518721C
- Authority
- CN
- China
- Prior art keywords
- enteric
- aconitine
- quick releasing
- acid
- releasing sheet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- XFSBVAOIAHNAPC-XTHSEXKGSA-N 16-Ethyl-1alpha,6alpha,19beta-trimethoxy-4-(methoxymethyl)-aconitane-3alpha,8,10alpha,11,18alpha-pentol, 8-acetate 10-benzoate Chemical compound O([C@H]1[C@]2(O)C[C@H]3[C@@]45C6[C@@H]([C@@]([C@H]31)(OC(C)=O)[C@@H](O)[C@@H]2OC)[C@H](OC)[C@@H]4[C@]([C@@H](C[C@@H]5OC)O)(COC)CN6CC)C(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-XTHSEXKGSA-N 0.000 title claims abstract description 22
- XFSBVAOIAHNAPC-UHFFFAOYSA-N Aconitin Natural products CCN1CC(C(CC2OC)O)(COC)C3C(OC)C(C(C45)(OC(C)=O)C(O)C6OC)C1C32C4CC6(O)C5OC(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-UHFFFAOYSA-N 0.000 title claims abstract description 22
- 229940039750 aconitine Drugs 0.000 title claims abstract description 22
- STDXGNLCJACLFY-UHFFFAOYSA-N aconitine Natural products CCN1CC2(COC)C(O)CC(O)C34C5CC6(O)C(OC)C(O)C(OC(=O)C)(C5C6OC(=O)c7ccccc7)C(C(OC)C23)C14 STDXGNLCJACLFY-UHFFFAOYSA-N 0.000 title claims abstract description 22
- 238000002360 preparation method Methods 0.000 title description 11
- 239000003814 drug Substances 0.000 claims abstract description 18
- 229920000642 polymer Polymers 0.000 claims abstract description 5
- 239000004014 plasticizer Substances 0.000 claims abstract description 3
- -1 polyethylene phthalate Polymers 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 5
- 150000002148 esters Chemical class 0.000 claims description 5
- 239000004925 Acrylic resin Substances 0.000 claims description 4
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims description 3
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims description 3
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 2
- 229920000858 Cyclodextrin Polymers 0.000 claims description 2
- 235000016623 Fragaria vesca Nutrition 0.000 claims description 2
- 240000009088 Fragaria x ananassa Species 0.000 claims description 2
- 235000011363 Fragaria x ananassa Nutrition 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- XINCECQTMHSORG-UHFFFAOYSA-N Isoamyl isovalerate Chemical compound CC(C)CCOC(=O)CC(C)C XINCECQTMHSORG-UHFFFAOYSA-N 0.000 claims description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 2
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 claims description 2
- 229920002301 cellulose acetate Polymers 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 2
- 229960003943 hypromellose Drugs 0.000 claims description 2
- 229940116298 l- malic acid Drugs 0.000 claims description 2
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
- 239000011976 maleic acid Substances 0.000 claims description 2
- 229940117841 methacrylic acid copolymer Drugs 0.000 claims description 2
- 229920003145 methacrylic acid copolymer Polymers 0.000 claims description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
- 239000000470 constituent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 abstract description 8
- 238000002156 mixing Methods 0.000 abstract description 6
- 239000011248 coating agent Substances 0.000 abstract description 5
- 239000002904 solvent Substances 0.000 abstract description 3
- 239000000654 additive Substances 0.000 abstract 1
- 230000000996 additive effect Effects 0.000 abstract 1
- 238000010298 pulverizing process Methods 0.000 abstract 1
- YRECILNLFWZVRM-XTNYDWJGSA-N bulleyaconitine a Chemical compound O=C([C@H]1[C@]2(O)C[C@H]3[C@]45[C@H](OC)CC[C@@]6(COC)CN([C@@H]5[C@H]([C@H](OC)[C@H]64)[C@](C[C@@H]2OC)(OC(C)=O)[C@H]31)CC)C1=CC=C(OC)C=C1 YRECILNLFWZVRM-XTNYDWJGSA-N 0.000 description 21
- 239000007941 film coated tablet Substances 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 11
- 239000000047 product Substances 0.000 description 9
- 239000003826 tablet Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 230000000968 intestinal effect Effects 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- RIPYIJVYDYCPKW-UHFFFAOYSA-N 3-Acetylaconitine Natural products CCN1CC(C(CC2OC)OC(C)=O)(COC)C3C(OC)C(C(C45)(OC(C)=O)C(O)C6OC)C1C32C4CC6(O)C5OC(=O)C1=CC=CC=C1 RIPYIJVYDYCPKW-UHFFFAOYSA-N 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000036407 pain Effects 0.000 description 4
- RIPYIJVYDYCPKW-UOGIXDCTSA-N x1071 Chemical compound O([C@H]1[C@]2(O)C[C@H]3[C@@]45C6[C@@H]([C@@]([C@H]31)(OC(C)=O)[C@@H](O)[C@@H]2OC)[C@H](OC)[C@@H]4[C@]([C@@H](C[C@@H]5OC)OC(C)=O)(COC)CN6CC)C(=O)C1=CC=CC=C1 RIPYIJVYDYCPKW-UOGIXDCTSA-N 0.000 description 4
- QUSPUZQKMRMVFL-UHFFFAOYSA-N 2-(benzenesulfonamido)-4-methylsulfanylbutanoic acid Chemical compound CSCCC(C(O)=O)NS(=O)(=O)C1=CC=CC=C1 QUSPUZQKMRMVFL-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000003467 diminishing effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000009505 enteric coating Methods 0.000 description 3
- 239000002702 enteric coating Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 3
- 210000004211 gastric acid Anatomy 0.000 description 3
- 210000004051 gastric juice Anatomy 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000002085 irritant Substances 0.000 description 3
- 231100000021 irritant Toxicity 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 241000227129 Aconitum Species 0.000 description 2
- 241000701413 Aconitum kusnezoffii Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 102000011759 adducin Human genes 0.000 description 2
- 108010076723 adducin Proteins 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000007907 direct compression Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical group O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- NWBWCXBPKTTZNQ-UHFFFAOYSA-N (16S)-4-(N-Acetyl-anthraniloyloxy)-20-aethyl-1alpha,14alpha,16-trimethoxy-aconitan-8,9-diol Natural products C1CC(OC)C2(C3C4)C5CC(C(C6)OC)C(OC)C5(O)C6(O)C4C2N(CC)CC31OC(=O)C1=CC=CC=C1NC(C)=O NWBWCXBPKTTZNQ-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 241000173529 Aconitum napellus Species 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010036781 Fumarate Hydratase Proteins 0.000 description 1
- 102100036160 Fumarate hydratase, mitochondrial Human genes 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010022061 Injection site erythema Diseases 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 229940023019 aconite Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 238000001354 calcination Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000007948 fast release tablet Substances 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000004531 microgranule Substances 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- NWBWCXBPKTTZNQ-QOQRDJBUSA-N y4m5974f7z Chemical compound O([C@]12CN([C@@H]3[C@H]4[C@]5(O)[C@@]6(O)[C@@H](OC)[C@@H]([C@H](C5)OC)C[C@H]6[C@@]3([C@@H]1C4)[C@@H](OC)CC2)CC)C(=O)C1=CC=CC=C1N=C(C)O NWBWCXBPKTTZNQ-QOQRDJBUSA-N 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
组别 | 体重 | 剂量(mg/Kg) | 扭体次数 | 抑制率 |
空白组 | 20±1.0 | 等体积 | 30.7±7.88 | |
吗啡组 | 20±1.3 | 10 | 2.4±1.50 | 92.5% |
草乌甲素片 | 20±1.1 | 0.2 | 10.5±3.42 | 76.04% |
肠溶速释片 | 20±1.2 | 0.2 | 7.5±3.00 | 87.2% |
组别 | 体重 | 剂量(mg/Kg) | 光密度值 | 抑制率 |
空白组 | 20±1.12 | 等体积 | 0.28±0.05 | |
阿司匹林 | 20±1.13 | 200 | 0.13±0.03 | 62.5% |
草乌甲素片 | 20±1.12 | 0.2 | 0.10±0.02 | 71.4% |
肠溶速释片 | 20±1.1 | 0.2 | 0.09±0.002 | 79.5% |
反应级 | 刺激反应 |
0 | 无变化 |
1 | 无明显变化 |
2 | 有轻度充血点 |
3 | 有中度充血点 |
4 | 有重度充血点,伴有小面积部位变化 |
样品 | 1月 | 2月 | 3月 | 6月 | 12月 | 24月 |
例1 | 合格 | 合格 | 合格 | 合格 | 合格 | 合格 |
例2 | 合格 | 合格 | 合格 | 合格 | 合格 | 合格 |
例3 | 合格 | 合格 | 合格 | 合格 | 合格 | 合格 |
例4 | 合格 | 合格 | 合格 | 合格 | 合格 | 合格 |
例5 | 台格 | 合格 | 合格 | 合格 | 合格 | 合格 |
例6 | 台格 | 合格 | 台格 | 台格 | 台格 | 合格 |
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2006100486072A CN100518721C (zh) | 2006-08-08 | 2006-08-08 | 一种含有乌头碱的肠溶速释片及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2006100486072A CN100518721C (zh) | 2006-08-08 | 2006-08-08 | 一种含有乌头碱的肠溶速释片及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1903181A CN1903181A (zh) | 2007-01-31 |
CN100518721C true CN100518721C (zh) | 2009-07-29 |
Family
ID=37672641
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2006100486072A Active CN100518721C (zh) | 2006-08-08 | 2006-08-08 | 一种含有乌头碱的肠溶速释片及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100518721C (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102406640A (zh) * | 2010-09-26 | 2012-04-11 | 上海泰因生物技术有限公司 | 镇痛消炎类药物及镇痛消炎类药物微针透皮给药方法 |
CN102526233B (zh) * | 2010-12-24 | 2016-01-27 | 无锡济民可信山禾药业股份有限公司 | 一种含有乌头碱的多单元肠溶制剂及其制备方法 |
CN102178658B (zh) * | 2011-05-03 | 2013-04-10 | 中国人民解放军第三军医大学第二附属医院 | 氢溴酸高乌甲素口腔崩解片及其制备方法 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1107697A (zh) * | 1993-10-23 | 1995-09-06 | 云南省弥勒县制药厂 | 草乌甲素口服片剂、胶囊剂 |
CN1228958A (zh) * | 1998-03-17 | 1999-09-22 | 昆明制药股份有限公司 | 草乌甲素软胶囊及其生产方法 |
CN1535684A (zh) * | 2003-04-09 | 2004-10-13 | 王 锦 | 草乌甲素粉针剂及其制备方法 |
CN1596895A (zh) * | 2003-09-20 | 2005-03-23 | 昆明紫健生物技术有限公司 | 草乌甲素微囊及其生产方法 |
CN1602865A (zh) * | 2003-09-30 | 2005-04-06 | 昆明紫健生物技术有限公司 | 草乌甲素脂肪乳输液及其生产方法 |
CN1686120A (zh) * | 2005-04-19 | 2005-10-26 | 北京正大绿洲医药科技有限公司 | 氢溴酸高乌甲素滴丸及其制备方法 |
CN1778299A (zh) * | 2004-11-19 | 2006-05-31 | 昆明五和堂药物研制有限公司 | 草乌甲素鼻腔给药制剂 |
-
2006
- 2006-08-08 CN CNB2006100486072A patent/CN100518721C/zh active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1107697A (zh) * | 1993-10-23 | 1995-09-06 | 云南省弥勒县制药厂 | 草乌甲素口服片剂、胶囊剂 |
CN1228958A (zh) * | 1998-03-17 | 1999-09-22 | 昆明制药股份有限公司 | 草乌甲素软胶囊及其生产方法 |
CN1535684A (zh) * | 2003-04-09 | 2004-10-13 | 王 锦 | 草乌甲素粉针剂及其制备方法 |
CN1596895A (zh) * | 2003-09-20 | 2005-03-23 | 昆明紫健生物技术有限公司 | 草乌甲素微囊及其生产方法 |
CN1602865A (zh) * | 2003-09-30 | 2005-04-06 | 昆明紫健生物技术有限公司 | 草乌甲素脂肪乳输液及其生产方法 |
CN1778299A (zh) * | 2004-11-19 | 2006-05-31 | 昆明五和堂药物研制有限公司 | 草乌甲素鼻腔给药制剂 |
CN1686120A (zh) * | 2005-04-19 | 2005-10-26 | 北京正大绿洲医药科技有限公司 | 氢溴酸高乌甲素滴丸及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN1903181A (zh) | 2007-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2609695T3 (es) | Comprimidos de oxicodona resistentes al aplastamiento destinados a evitar el uso incorrecto involuntario y la desviación ilícita de uso | |
AU2018200402B2 (en) | Abuse-resistant mucoadhesive devices for delivery of buprenorphine | |
JP6696994B2 (ja) | 即放性乱用抑止性顆粒剤形 | |
CN105209021A (zh) | 包含阿片样物质和另一种活性药物成分、用于迅速起效和延长的镇痛持续时间、可不考虑进食而给药的组合物 | |
ES2635733T3 (es) | Uso de antagonistas opioideos para tratar la retención urinaria | |
EP3340968B1 (en) | Implantable naltrexone tablets | |
TW201821072A (zh) | 乳酸鈣組成物及使用方法 | |
CN105326837A (zh) | 一种盐酸美金刚缓释-多奈哌齐速释复方胶囊 | |
CN103040829A (zh) | 含有高乌甲素和羟考酮的药物组合物 | |
CN100518721C (zh) | 一种含有乌头碱的肠溶速释片及其制备方法 | |
CN101229141B (zh) | 一种阿司匹林缓释片及其制备方法 | |
CN105311622B (zh) | 一种治疗疼痛的联合用药物及其制剂、制备方法 | |
WO2016084099A1 (en) | Soft gelatin capsule composition of anti-tussive agents | |
CA2709903A1 (en) | Oral opioid compositions with opioid antagonist | |
KR20090086128A (ko) | 메만틴 약학 조성물 | |
Murata et al. | Development of film dosage forms containing miconazole for the treatment of oral candidiasis | |
CN105641701A (zh) | 一种稳定的制霉菌素药物组合物及其制备方法 | |
CN103432596B (zh) | 新癀片中药成分镇痛作用的机理研究方法 | |
CN100391454C (zh) | 氢溴酸右美沙芬和β-环糊精配合物的药物制剂 | |
CN105125477A (zh) | 一种含消旋卡多曲的药物制剂及制备方法 | |
Samy et al. | Formulation and evaluation of Dicyclomine hydrochloride matrix tablets for colon specific drug delivery | |
Jenita et al. | INVESTIGATION OF NAPROXEN COMPRESSION COATED TABLETS USING POLYSACCHARIDES AS CARRIERS FOR ORAL BASED SITE SPECIFIC DELIVERY TO COLON | |
CN102940614B (zh) | 一种含草乌甲素的片剂制剂方法 | |
Sarashetti et al. | INTERNATIONAL JOURNAL OF RESEARCH IN PHARMACEUTICAL SCIENCES | |
CN109692167A (zh) | 治疗认知功能障碍的药物组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Enteric quick-dissolving tablets contg. aconitine, and its prepn. method Effective date of registration: 20121210 Granted publication date: 20090729 Pledgee: China Merchants Bank Limited by Share Ltd. Kunming Lin Yu Road Branch Pledgor: YUNNAN HAOPY PHARMACEUTICALS Ltd. Registration number: 2012990000772 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20140310 Granted publication date: 20090729 Pledgee: China Merchants Bank Limited by Share Ltd. Kunming Lin Yu Road Branch Pledgor: YUNNAN HAOPY PHARMACEUTICALS Ltd. Registration number: 2012990000772 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Enteric quick-dissolving tablets contg. aconitine, and its prepn. method Effective date of registration: 20140310 Granted publication date: 20090729 Pledgee: China Merchants Bank Limited by Share Ltd. Kunming Lin Yu Road Branch Pledgor: YUNNAN HAOPY PHARMACEUTICALS Ltd. Registration number: 2014990000149 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20150511 Granted publication date: 20090729 Pledgee: China Merchants Bank Limited by Share Ltd. Kunming Lin Yu Road Branch Pledgor: YUNNAN HAOPY PHARMACEUTICALS Ltd. Registration number: 2014990000149 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Enteric quick-dissolving tablets contg. aconitine, and its prepn. method Effective date of registration: 20150708 Granted publication date: 20090729 Pledgee: Fudian bank Limited by Share Ltd. Kunming Haiyuan Road Branch Pledgor: YUNNAN HAOPY PHARMACEUTICALS Ltd. Registration number: 2015990000544 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20160630 Granted publication date: 20090729 Pledgee: Fudian bank Limited by Share Ltd. Kunming Haiyuan Road Branch Pledgor: YUNNAN HAOPY PHARMACEUTICALS Ltd. Registration number: 2015990000544 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Enteric coated instant release tablet containing Aconitine and its preparation method Effective date of registration: 20230616 Granted publication date: 20090729 Pledgee: Kunming Branch of China Minsheng Bank Co.,Ltd. Pledgor: YUNNAN HAOPY PHARMACEUTICALS Ltd. Registration number: Y2023530000041 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Granted publication date: 20090729 Pledgee: Kunming Branch of China Minsheng Bank Co.,Ltd. Pledgor: YUNNAN HAOPY PHARMACEUTICALS Ltd. Registration number: Y2023530000041 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |